Jove
Visualize
Contact Us

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

157
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
157
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
Psychosurgery01:30

Psychosurgery

95
Psychosurgery, the surgical alteration or permanent removal of brain tissue to alleviate severe psychological conditions, stands as one of the most radical and controversial treatments in the history of mental health care. Its development and application have evolved significantly, marked by dramatic shifts in scientific understanding and ethical perspectives.
Historical Development of Psychosurgery
In the 1930s, Portuguese neurologist Antonio Egas Moniz introduced a surgical procedure designed...
95
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psoriasis Triggers and Disease Activity: Analysis of Survey Data from the PSODEEP1 Study.

Acta dermato-venereologica·2026
Same author

Angioedema in Primary Care: Disease Course and Its Relation to ACE Inhibitor Use.

International journal of dermatology·2026
Same author

Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study.

Psoriasis (Auckland, N.Z.)·2026
Same author

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Bridging theory and practice in model-informed precision dosing of medication in inflammatory skin diseases.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Aug 18, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure.

L S van der Schoot1, E M Baerveldt2, W A van Enst3

  • 1Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands.

The Journal of Dermatological Treatment
|December 6, 2022
PubMed
Summary

Consensus was reached on 15 recommendations for biologic dose reduction in psoriasis patients with stable disease. These criteria guide clinicians in consistent application of dose reduction strategies for better patient outcomes.

Keywords:
Biologicsconsensusdose reductioneDelphipsoriasis

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

477
Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

41.9K

Related Experiment Videos

Last Updated: Aug 18, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

477
Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

41.9K

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Biologic therapies are common for psoriasis, but guidelines for dose reduction are lacking.
  • Clear criteria are needed for consistent biologic dose reduction in clinical practice.

Purpose of the Study:

  • To establish consensus on criteria for biologic dose reduction in psoriasis patients with stable, low disease activity.

Main Methods:

  • An online Delphi procedure (eDelphi) involving Dutch dermatologists was used.
  • Consensus was defined as ≥70% agreement and <15% disagreement on proposed statements.
  • Statements covered criteria for dose reduction and specific dosing schedules.

Main Results:

  • 27 dermatologists reached consensus on 15 recommendations over two rounds.
  • Criteria were established for dose reduction eligibility, continuation, and discontinuation.
  • Dosing schedules for adalimumab, etanercept, and ustekinumab were agreed upon.

Conclusions:

  • The consensus recommendations provide guidance for consistent biologic dose reduction in psoriasis management.
  • An algorithm for clinical implementation was developed based on the eDelphi outcomes.